Re­gen­eron heads to­ward FDA fil­ing for mul­ti­ple myelo­ma bis­pe­cif­ic, set­ting up show­down with J&J, Pfiz­er: #ASH23

Near­ly half of the pa­tients who re­ceived an ex­per­i­men­tal mul­ti­ple myelo­ma treat­ment de­vel­oped by Re­gen­eron in a clin­i­cal study saw signs of their can­cer com­plete­ly dis­ap­pear, ac­cord­ing to re­sults re­port­ed by the com­pa­ny Thurs­day morn­ing.

Re­gen­eron said it ex­pects to com­plete a reg­u­la­to­ry fil­ing to the FDA in the com­ing weeks based on the da­ta shared ahead of the Amer­i­can So­ci­ety of Hema­tol­ogy’s an­nu­al meet­ing.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.